Abstract:ABSTRACT The novel bacterial topoisomerase inhibitor class is an investigational type of antibacterial inhibitor of DNA gyrase and topoisomerase IV that does not have cross-resistance with the quinolones. Here, we report the evaluation of the in vitro properties of a new series of this type of small molecule. Exemplar compounds selectively and potently inhibited the catalytic activities of Escherichia coli DNA gyrase and topoisomerase IV but did not block the DNA breakage-reunion step. Compounds showed broad-spectrum inhibitory activity against a wide range of Gram-positive and Gram-negative pathogens, including biodefence microorganisms and Mycobacterium tuberculosis. No cross-resistance with fluoroquinolone-resistant Staphylococcus aureus and E. coli isolates was observed. Measured MIC90 values were 4 and 8 μg/ml against a panel of contemporary multidrug-resistant isolates of Acinetobacter baumannii and E. coli, respectively. In addition, representative compounds exhibited greater antibacterial potency than the quinolones against obligate anaerobic species. Spontaneous mutation rates were low, with frequencies of resistance typically <10−8 against E. coli and A. baumannii at concentrations equivalent to 4-fold the MIC. Compound-resistant E. coli mutants that were isolated following serial passage were characterized by whole-genome sequencing and carried a single Arg38Leu amino acid substitution in the GyrA subunit of DNA gyrase. Preliminary in vitro safety data indicate that the series shows a promising therapeutic index and potential for low human ether-a-go-go-related gene (hERG) inhibition (50% inhibitory concentration [IC50], >100 μM). In summary, the compounds' distinct mechanism of action relative to the fluoroquinolones, whole-cell potency, low potential for resistance development, and favorable in vitro safety profile warrant their continued investigation as potential broad-spectrum antibacterial agents.

In Silico Study of the Potential Inhibitory Effects on Escherichia coli DNA Gyrase of Some Hypothetical Fluoroquinolone–Tetracycline Hybrids

Discovery of Benzimidazole–Quinolone Hybrids As New Cleaving Agents Toward Drug‐Resistant Pseudomonas Aeruginosa DNA

Unique Aminothiazolyl Coumarins As Potential DNA and Membrane Disruptors Towards Enterococcus Faecalis

Discovery of Natural Berberine-Derived Nitroimidazoles As Potentially Multi-Targeting Agents Against Drug-Resistant Escherichia Coli

Design, Synthesis, and Evaluation of Novel Fluoroquinolone-Flavonoid Hybrids As Potent Antibiotics Against Drug-Resistant Microorganisms.

Novel Fluoroquinolones with Possible Antibacterial Activity in Gram-Negative Resistant Pathogens: In Silico Drug Discovery

Novel 3-arylfuran-2(5H)-one-fluoroquinolone hybrid: design, synthesis and evaluation as antibacterial agent.

Current Scenario of Quinolone Hybrids with Potential Antibacterial Activity Against ESKAPE Pathogens

Experimental and Molecular Docking Studies of Cyclic Diphenyl Phosphonates as DNA Gyrase Inhibitors for Fluoroquinolone-Resistant Pathogens

In Silico Evaluation of Some Computer-Designed Fluoroquinolone–Glutamic Acid Hybrids as Potential Topoisomerase II Inhibitors with Anti-Cancer Effect

Discovery of isoquinoline sulfonamides as allosteric gyrase inhibitors with activity against fluoroquinolone-resistant bacteria

Developing Effective Antimicrobial Agents: Synthesis and Molecular Docking Study of Ciprofloxacin‐Benzimidazole Hybrids

Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria

Discovery of N-quinazolinone-4-hydroxy-2-quinolone-3-carboxamides As DNA Gyrase B-targeted Antibacterial Agents

Antimicrobial flavonoid: in silico targeting Escherichia coli DNA gyrase adeptly

Synthesis, anti-microbial evaluation, and in silico studies of novel quinoline-isoxazole hybrids

Antibacterial and anti-biofilm activities of new fluoroquinolone derivatives coupled with nitrogen-based heterocycles

New Benzofuran–Pyrazole-Based Compounds as Promising Antimicrobial Agents: Design, Synthesis, DNA Gyrase B Inhibition, and In Silico Studies

Synthesis and in Vitro Antibacterial Activity of 7-(3-alkoxyimino-5-amino/methylaminopiperidin-1-yl)fluoroquinolone Derivatives

Design and Synthesis of Novel Desfluoroquinolone-Aminopyrimidine Hybrids As Potent Anti-Mrsa Agents with Low Herg Activity

Synthesis and in Vitro Antibacterial Activity of 7-(4-alkoxyimino-3-amino-3-methylpiperidin-1-yl)fluoroquinolone Derivatives.